The company
Pharvaris N.V. -
PHVS · Nasdaq
PHVS stood above a rising 150-day average in 49 of the last 52 weekly readings, and has been out of that trend for the last 3 weeks. It is 13.3% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).
Statistics
- Rotation
- Not moving yet
- Weeks in an uptrend
- out for 3
- Industry in uptrend
- 15% -17 in 4 wk
- Insider buys, 12 months
- $0
- Insider sales, 12 months
- $66.0M
- Officials’ trades on record
- 0
- Institutions holding
- 120 (+14)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 49 of 52 weeks.
Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.
Money in and out
Open-market buys above the line and sales below, in dollars.
Congress and officials
No member of Congress or official has disclosed a trade in it.
Insiders
| Who | Did | Shares | Traded |
|---|---|---|---|
| Viviane MongesDirector | sold | 11,969at $33.05 | 23 Sep 2026filed 25 Sep 2026 |
| Johannes Gerardus Christiaan Petrus SchikanDirector | sold | 800at $36.19 | 22 Sep 2026filed 24 Sep 2026 |
| David W. NassifCFO / CLO | sold | 6,000at $36.47 | 21 Sep 2026filed 23 Sep 2026 |
| Anne LesageChief Early Development | sold | 20,000at $38.27 | 17 Sep 2026filed 21 Sep 2026 |
| Robert GlassmanDirector | sold | 14,493at $38.56 | 17 Sep 2026filed 21 Sep 2026 |
| Elisabeth BjorkDirector | sold | 52,500at $37.89 | 17 Sep 2026filed 21 Sep 2026 |
| Johannes Gerardus Christiaan Petrus SchikanDirector | sold | 200,000at $35.00 | 17 Sep 2026filed 21 Sep 2026 |
| Peng LuPresident | sold | 100,000at $35.00 | 17 Sep 2026filed 21 Sep 2026 |
| Wim SouverijnsChief Commercial Officer | sold | 6,090at $38.99 | 15 Sep 2026filed 16 Sep 2026 |
| Robert GlassmanDirector | sold | 8,667at $38.27 | 15 Sep 2026filed 17 Sep 2026 |
| Stefan Andreas AbeleChief Technical Ops Officer | sold | 45,000at $38.14 | 15 Sep 2026filed 17 Sep 2026 |
| Stefan Andreas AbeleChief Technical Ops Officer | sold | 1,400at $39.24 | 15 Sep 2026filed 17 Sep 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| FMR LLCadded · filed 13 Aug 2026 | 6,565,272$227.0M | +280,800+4.5% |
| GENERAL ATLANTIC, L.P.reduced · filed 14 Aug 2026 | 6,550,757$226.5M | -1,480,495−18.4% |
| Foresite Capital Management IV, LLCunchanged · filed 14 Aug 2026 | 4,778,581$165.2M | 00.0% |
| venBio Partners LLCadded · filed 14 Aug 2026 | 4,643,430$160.6M | +4,126+0.1% |
| VIKING GLOBAL INVESTORS LPunchanged · filed 14 Aug 2026 | 3,653,310$126.3M | 00.0% |
| EQT Fund Management S.a r.l.unchanged · filed 13 Aug 2026 | 3,424,609$118.4M | 00.0% |
| DEERFIELD MANAGEMENT COMPANY, L.P.added · filed 14 Aug 2026 | 3,376,042$116.7M | +250,000+8.0% |
| Bain Capital Life Sciences Investors, LLCunchanged · filed 14 Aug 2026 | 2,675,509$92.5M | 00.0% |
| WELLINGTON MANAGEMENT GROUP LLPadded · filed 14 Aug 2026 | 2,392,934$82.7M | +274,034+12.9% |
| Polar Capital Holdings Plcadded · filed 14 Aug 2026 | 2,326,389$80.4M | +1,545,373+197.9% |
News
No headline names it lately.
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.